Pharmaceutical stocks are seen trading in a narrow range next week due to lack of any major trigger. Pharmaceutical stocks have entered a consolidation mode. The stocks should remain at the current levels for some time and then move up again. As of now, I believe pharma stocks should be rangebound as we do not see anything big, positive happening in the next few days.
BSE Healthcare Index is currently trading sideways to positive and it would continue the trend next week as well. Talking about stock specific movements, Cipla is set to see some downside in the weeks to come due to a one-off gain in Apr-Jun.
The nearly 450 basis points improvement in the company's operating margin was a result of lower proportion of antiretroviral drugs and higher contribution from anti-depressant segment drugs like escitalopram, or Lexapro, coupled with higher realisations because of improvement in utilisation of the company's Indore unit.
Shares of GlaxoSmithKline Pharmaceuticals may see some downside next week as the company has stopped operations at its Thane factory, with all employees having opted for the voluntary retirement scheme offered by the company.
Shares of Ranbaxy Laboratories are seen gaining next week due to the launch of an anti-diabetic generic pioglitazone hydrochloride tablets in the US market. Shares of Ranbaxy are seen trading in a broad range of 470-525 rupees.
www.rupeedesk.in
BSE Healthcare Index is currently trading sideways to positive and it would continue the trend next week as well. Talking about stock specific movements, Cipla is set to see some downside in the weeks to come due to a one-off gain in Apr-Jun.
The nearly 450 basis points improvement in the company's operating margin was a result of lower proportion of antiretroviral drugs and higher contribution from anti-depressant segment drugs like escitalopram, or Lexapro, coupled with higher realisations because of improvement in utilisation of the company's Indore unit.
Shares of GlaxoSmithKline Pharmaceuticals may see some downside next week as the company has stopped operations at its Thane factory, with all employees having opted for the voluntary retirement scheme offered by the company.
Shares of Ranbaxy Laboratories are seen gaining next week due to the launch of an anti-diabetic generic pioglitazone hydrochloride tablets in the US market. Shares of Ranbaxy are seen trading in a broad range of 470-525 rupees.
www.rupeedesk.in
